GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (NAS:XOMA) » Definitions » Quick Ratio

XOMA (XOMA) Quick Ratio

: 8.68 (As of Dec. 2023)
View and export this data going back to 1986. Start your Free Trial

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. XOMA's quick ratio for the quarter that ended in Dec. 2023 was 8.68.

XOMA has a quick ratio of 8.68. It generally indicates good short-term financial strength.

The historical rank and industry rank for XOMA's Quick Ratio or its related term are showing as below:

XOMA' s Quick Ratio Range Over the Past 10 Years
Min: 0.84   Med: 6.96   Max: 8.98
Current: 8.68

During the past 13 years, XOMA's highest Quick Ratio was 8.98. The lowest was 0.84. And the median was 6.96.

XOMA's Quick Ratio is ranked better than
78.36% of 1553 companies
in the Biotechnology industry
Industry Median: 3.59 vs XOMA: 8.68

XOMA Quick Ratio Historical Data

The historical data trend for XOMA's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.76 7.16 7.48 8.98 8.68

XOMA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.98 4.47 5.42 3.34 8.68

Competitive Comparison

For the Biotechnology subindustry, XOMA's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA Quick Ratio Distribution

For the Biotechnology industry and Healthcare sector, XOMA's Quick Ratio distribution charts can be found below:

* The bar in red indicates where XOMA's Quick Ratio falls into.



XOMA Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

XOMA's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(169.313-0)/19.499
=8.68

XOMA's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(169.313-0)/19.499
=8.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA  (NAS:XOMA) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


XOMA Quick Ratio Related Terms

Thank you for viewing the detailed overview of XOMA's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA (XOMA) Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104

XOMA (XOMA) Headlines

From GuruFocus

XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Stock market mentor Stock market mentor 01-07-2023

XOMA to Present at 43rd Annual Cowen Health Care Conference

By sperokesalga sperokesalga 02-28-2023

XOMA to Present at Oppenheimer's 32nd Annual Healthcare Conference

By GuruFocusNews GuruFocusNews 03-10-2022

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-26-2022

XOMA Declares Quarterly Preferred Stock Dividends

By GuruFocusNews GuruFocusNews 07-10-2022

XOMA Declares Quarterly Preferred Stock Dividends

By GuruFocusNews GuruFocusNews 03-21-2022

XOMA Declares Quarterly Preferred Stock Dividends

By GuruFocusNews GuruFocusNews 06-30-2022